Turn Therapeutics (NASDAQ:TTRX) Stock Rating Raised to “Hold” at WBB Securities

Turn Therapeutics (NASDAQ:TTRX) was upgraded by investment analysts at WBB Securities from a “sell” rating to a “hold” rating in a report released on Friday, Marketbeat.com reports. The brokerage currently has a $10.00 target price on the stock. WBB Securities‘s target price suggests a potential downside of 5.40% from the stock’s current price.

A number of other equities research analysts also recently issued reports on TTRX. Wall Street Zen downgraded Turn Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, October 18th. Weiss Ratings downgraded Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. Lucid Cap Mkts upgraded Turn Therapeutics to a “strong-buy” rating in a research note on Thursday, September 24th. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. Finally, LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Turn Therapeutics Stock Performance

NASDAQ TTRX traded up $0.42 during trading hours on Friday, hitting $10.57. The company’s stock had a trading volume of 35,943 shares, compared to its average volume of 66,966. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $16.45. The company’s 50 day simple moving average is $11.63 and its two-hundred day simple moving average is $8.13. The company has a market cap of $322.73 million and a P/E ratio of -37.27. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. As a group, sell-side analysts expect that Turn Therapeutics will post -0.40 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. SteelPeak Wealth LLC lifted its holdings in Turn Therapeutics by 0.7% in the 3rd quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock worth $3,616,000 after purchasing an additional 1,819 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new position in Turn Therapeutics in the 3rd quarter worth approximately $40,000. Jefferies Financial Group Inc. purchased a new position in Turn Therapeutics in the 2nd quarter worth approximately $119,000. Bank of America Corp DE purchased a new position in Turn Therapeutics in the 2nd quarter worth approximately $103,000. Finally, Ieq Capital LLC purchased a new position in Turn Therapeutics in the 2nd quarter worth approximately $1,660,000.

Turn Therapeutics Company Profile

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.